MYD88 and breast carcinoma: This integrative study combines bulk RNA sequencing (RNA-seq), single-cell RNA sequencing (scRNA-seq), and immunohistochemistry (IHC) to explore the prognostic significance and immunological implications of MyD88 in breast cancer.